Candel’s promising Ph2 data in pancreatic cancer; Microbiome biotech raises £27M

04 Apr 2024

Phase 2Clinical ResultImmunotherapy

Plus, news about Manifold and Phenomix: Candel Therapeutics’ viral immunotherapy impresses in pancreatic cancer: In a small Phase 2 trial for patients with borderline resectable pancreatic cancer, those who received Candel’s experimental therapy had 28.8 months of estimated overall survival time compared to the 12.5 months in those who received standard chemo. Four of seven patients who received CAN-2409 were still alive at the March 29 data cut-off, with two patients surviving more than four years from enrollment. Only one out of six patients who received chemotherapy was still alive. Candel’s stock $CADL rose nearly 40% on Thursday morning. — Lei Lei Wu

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Manifold Health Tech Usa, Inc.

Phenomix Corp.

Candel Therapeutics, Inc.

Indications

Pancreatic Cancer

Targets

Drugs

Aglatimagene besadenovec

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.